Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Reagents, Recombinant Proteins, Ria Kits, RNA
The Relationship of Cholangiocarcinoma with Human Immunodeficiency Virus Cholangiopathy and Cytomegalovirus Infection
The human immunodeficiency virus (HIV) is a disease worldwide with the increasing number of cases globally. Initially, HIV colliaiopati was often observed among these patients but has become rare after three decades due to the availability of new care choices and strong antiretroviral drugs. As a result, the incident now suggests drug resistance or the development of the disease. The relationship between Cholaghiocarcinoma and HIV is still unclear. We report cases of patients with high-grade dysplasia from Choledochus ducts and uncontrolled diseases treated with strong antivirus agents and dilated bile tract.
Learning points: HIV Choligiopathy must be remembered in HIV-positive patients even if they receive combination (train) antiretroviral therapy; Endoscopy Retrograde Choliaiopancreatography can provide symptomatic assistance. After HIV Chorangiopathy is detected, follow-up for Cholangiocarcinoma is needed. Corrected infections can cause choliaiocarcinoma in HIV-positive patients.
The decrease in the incidence of acute rejection without increasing the incidence of cytomegalovirus (CMV) infection in recipients of kidney transplants that accept the anti-thymocyte globulin (RATG) rabbit without prophylactic CMV
Induction therapy with the anti-thymocyte globulin (RATG) rabbit in recipients of low-risk ktridal transplants (KTR) remains controversial, given the increased risk of cytomegalovirus (CMV) infection. This natural experiment compares the clinical results of 12 months in low-risk KTR without CMV prophylaxis (Jan / 3/13-Sep / 16/15) accepting without induction or a single dose of 3mg / kg. We use logistic regression to characterize the pending graft function (DGF), negative binomials to characterize the length of hospitalization of hospitals (LOS) and Cox regression to characterize acute rejection (AR), CMV infection, mistrident of grafting, death and readmission.
The recipient received 3mg / kg Ratg had a risk of 81% lower than AR (AHR 0.14 0.190.25, p <0.001) but there was no increase in hospital admission due to infection (0.911.21, p = 0.5). There is no relationship between 3 mg / kg infection / CMV disease (AHR 0.86 1,101.40, p = 0.5), even when analysis is grouped based on the positive CMV serostatatus (AHR 0.94 1.25 1.65, p = 0, 15) and negative (AHR 0.28 0.57 1.16, p = 0.1). There is no relationship between 3MG / kg Ratg and mortality (AHR 0.51 1,253.08, p = 0.6), loss of grafts (AHR 0.34 0.731.55, p = 0.4). Among the low-risk ktr that does not accept the pharmacological prophylaxis of CMV, induction of 3mg / kg Ratg is associated with a significant reduction in the incidence of AR without an increased risk of CMV infection, regardless of the pre-transplant receiver CMV serostatus.
Lesions such as Degos as a skin manifestation of Cytomegalovirus infection: rare and serious complications in patients with drug induced hypersensitivity syndrome
Cytomegalovirus causes a myriad of clinical features, potentially influencing any organ system, significantly increases morbidity and even mortality. Vascular endothelial cell infections by CyTomeGalovirus have been involved in the development of Vasculopathy, perhaps accounting for clinical relations between Cytomegalovirus and vascular thrombosis. Unlike the involvement of visceral organs, cytomegalovirus skin manifestations varies and are rarely explained. Papulosis of malignant atrophy, which is commonly known as a Degos disease, is an unusual arteriopathic ship with a patognomonic clinical appearance from the middle porcelain-white papules surrounded by erythema Telangiectatic.
Like the arterial occlusive process, Degos may be idiopathic or secondary to autoimmune disorders or viral infections. All in all, presentations such as Degos related to Cytomegalovirus have never been explained. This report illustrates cases where disseminated cytomegalovirus disease is developed 4 weeks after the emergence of hypersensitivity syndrome induced by drugs with skin lesions such as prominent degos. Our case highlights a rare example of lesions such as Degos that occur because of cytomegalovirus disease and emphasizes the importance of early recognition of skin eruption characteristics as a diagnostic instrument that leads to the management of this life-threatening infection.
Cytomegalovirus pancreatitis in immunocompetent patients
Cytomegalovirus (CMV) is a DNA virus whose double strand, which infects most of the adult population. In immunocompetent patients, usually asymptomatic or manifest as symptoms of mild flu and self-limit, while in immunocompromised patients, CMV can cause significant disease. Here we report cases of unusual CMV pancreatitis in the 75-year-old woman’s immunocompetent. Patients develop severe significant pancreatic necrosis that failed non-operative management, and ultimately underwent the Pancreatic Necrosectomy. Then, he developed three spontaneous gastric perforations.

The first two perforations were managed operatively, but after the third perforation family decided not to undergo other operations. The diagnosis of CMV pancreatitis is based on pancreatic histopathology and confirms with a rapid response to Ganciclovir. The patient immediately began at Ganciclovir Intravenous (IV) which resulted in clinical recovery and he remained without symptoms of more than one year post op. This is a rare case of CMV pancreatitis with gastric perforation in immunocompetent patients. The level of suspicion is high and the right maintenance is important for such a clinical scenario.
Microvascular and structural abnormalities extralesional in cytomegalovirus retinitis
To evaluate extraesional microvascular and structural changes from the macula using Optical Coherence Tomography Angiography (Octa) and Structural October in the Citomegalovirus Retinitis (CMVR). A CMVR patient observational study was conducted. Complete ophthalmic examination, serial color fundus fundus, structural October and Octa are carried out at the beginning and follow-up visits up to 12 months. The structural OCT was analyzed to evaluate the macular area inside, bordering and exceed CMVR lesions.
Plexus extraledional retina capillaries from maculas are evaluated with October angiography and compared to fellow eyes that are not affected. Thirteen eyes from 13 registered patients. On the basis, the macular area without CMVR lesions showed a decrease in ship density (VD) of both superficial (p = 0,0002) and inside (p <0.0001) the retinal capillary plexus in the eye with CMVR compared to the area of the macular not affected by fellow eyes that are not affected. The decrease in VD survives through the follow-up period of up to 12 months after adjusting the degree of vitreous fog.
TTC3 Rabbit pAb |
A15734-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC5 Rabbit pAb |
A13232-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC5 Rabbit pAb |
A13232-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC5 Rabbit pAb |
A13232-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC5 Rabbit pAb |
A13232-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC1 Rabbit pAb |
A8745-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC1 Rabbit pAb |
A8745-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC1 Rabbit pAb |
A8745-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC1 Rabbit pAb |
A8745-50ul |
Abclonal |
50 ul |
EUR 267.6 |
TTC8 Rabbit pAb |
A5129-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC8 Rabbit pAb |
A5129-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC8 Rabbit pAb |
A5129-20ul |
Abclonal |
20 ul |
Ask for price |
TTC8 Rabbit pAb |
A5129-50ul |
Abclonal |
50 ul |
Ask for price |
anti- TTC39B antibody |
FNab09086 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against TTC39B |
TTC39B cloning plasmid |
CSB-CL713348HU-10ug |
Cusabio |
10ug |
EUR 333.6 |
|
Description: A cloning plasmid for the TTC39B gene. |
TTC11 / FIS1 Rabbit pAb |
A5821-100ul |
Abclonal |
100 ul |
EUR 369.6 |
TTC11 / FIS1 Rabbit pAb |
A5821-200ul |
Abclonal |
200 ul |
EUR 550.8 |
TTC11 / FIS1 Rabbit pAb |
A5821-20ul |
Abclonal |
20 ul |
EUR 219.6 |
TTC11 / FIS1 Rabbit pAb |
A5821-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rat TTC39B shRNA Plasmid |
20-abx988909 |
Abbexa |
|
|
|
Mouse TTC39B shRNA Plasmid |
20-abx977074 |
Abbexa |
|
|
|
Human TTC39B shRNA Plasmid |
20-abx965852 |
Abbexa |
|
|
|
TTC39B Antibody, HRP conjugated |
1-CSB-PA713348LB01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
TTC39B Recombinant Protein (Rat) |
RP235163 |
ABM |
100 ug |
Ask for price |
TTC39B Antibody, FITC conjugated |
1-CSB-PA713348LC01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
TTC39B Recombinant Protein (Mouse) |
RP182057 |
ABM |
100 ug |
Ask for price |
TTC39B Recombinant Protein (Human) |
RP033328 |
ABM |
100 ug |
Ask for price |
TTC39B Antibody, Biotin conjugated |
1-CSB-PA713348LD01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Ttc39b ORF Vector (Rat) (pORF) |
ORF078389 |
ABM |
1.0 ug DNA |
EUR 607.2 |
TTC39B ORF Vector (Human) (pORF) |
ORF011110 |
ABM |
1.0 ug DNA |
EUR 114 |
Ttc39b ORF Vector (Mouse) (pORF) |
ORF060687 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Polyclonal TTC39B Antibody (C-term) |
APR03519G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TTC39B (C-term). This antibody is tested and proven to work in the following applications: |
Ttc39b sgRNA CRISPR Lentivector set (Rat) |
K6591501 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Ttc39b sgRNA CRISPR Lentivector set (Mouse) |
K4952201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
TTC39B sgRNA CRISPR Lentivector set (Human) |
K2551101 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
TTC39B 3'UTR GFP Stable Cell Line |
TU077428 |
ABM |
1.0 ml |
EUR 1672.8 |
Ttc39b 3'UTR GFP Stable Cell Line |
TU171312 |
ABM |
1.0 ml |
Ask for price |
Ttc39b 3'UTR GFP Stable Cell Line |
TU272613 |
ABM |
1.0 ml |
Ask for price |
TTC39B Protein Vector (Rat) (pPM-C-HA) |
PV313556 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPB-C-His) |
PV313554 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPB-N-His) |
PV313555 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Rat) (pPM-C-His) |
PV313557 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Human) (pPM-C-HA) |
PV044439 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Mouse) (pPM-C-HA) |
PV242748 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Human) (pPB-C-His) |
PV044437 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Human) (pPB-N-His) |
PV044438 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Human) (pPM-C-His) |
PV044440 |
ABM |
500 ng |
EUR 394.8 |
TTC39B Protein Vector (Mouse) (pPB-C-His) |
PV242746 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPB-N-His) |
PV242747 |
ABM |
500 ng |
EUR 723.6 |
TTC39B Protein Vector (Mouse) (pPM-C-His) |
PV242749 |
ABM |
500 ng |
EUR 723.6 |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU121312 |
ABM |
1.0 ml |
Ask for price |
TTC39B 3'UTR Luciferase Stable Cell Line |
TU027428 |
ABM |
1.0 ml |
EUR 1672.8 |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU222613 |
ABM |
1.0 ml |
Ask for price |
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx239086-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx145789-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6591502 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6591503 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6591504 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4952202 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K4952203 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4952204 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 1) |
K2551102 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 2) |
K2551103 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 3) |
K2551104 |
ABM |
1.0 ug DNA |
EUR 184.8 |
TTC39B Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV681781 |
ABM |
1.0 ug DNA |
EUR 818.4 |
TTC39B Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV681785 |
ABM |
1.0 ug DNA |
EUR 818.4 |
TTC39B Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
LV681786 |
ABM |
1.0 ug DNA |
EUR 818.4 |
Mouse Tetratricopeptide repeat protein 39B, Ttc39b ELISA KIT |
ELI-40193m |
Lifescience Market |
96 Tests |
EUR 1038 |
Human Tetratricopeptide repeat protein 39B, TTC39B ELISA KIT |
ELI-23114h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) CLIA Kit |
20-abx496545 |
Abbexa |
-
EUR 10282.80
-
EUR 5472.00
-
EUR 1262.40
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
20-abx585014 |
Abbexa |
-
EUR 8853.60
-
EUR 4719.60
-
EUR 1093.20
|
- 10 × 96 tests
- 5 × 96 tests
- 96 tests
|
|
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
SER135Hu-10x96wellstestplate |
Cloud-Clone |
10x96-wells test plate |
EUR 6227.58 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) in tissue homogenates, cell lysates and other biological fluids. |
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
SER135Hu-1x48wellstestplate |
Cloud-Clone |
1x48-wells test plate |
EUR 618.04 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) in tissue homogenates, cell lysates and other biological fluids. |
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
SER135Hu-1x96wellstestplate |
Cloud-Clone |
1x96-wells test plate |
EUR 831.48 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) in tissue homogenates, cell lysates and other biological fluids. |
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
SER135Hu-5x96wellstestplate |
Cloud-Clone |
5x96-wells test plate |
EUR 3381.66 |
|
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) in tissue homogenates, cell lysates and other biological fluids. |
Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) ELISA Kit |
4-SER135Hu |
Cloud-Clone |
-
EUR 6288.00
-
EUR 3322.80
-
EUR 831.60
|
- 10 plates of 96 wells
- 5 plates of 96 wells
- 1 plate of 96 wells
|
|
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Tetratricopeptide Repeat Domain Protein 39B (TTC39B) in samples from tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species. |
Human Tetratricopeptide Repeat Domain Protein 39B ELISA Kit (TTC39B) |
RK02462 |
Abclonal |
96 Tests |
EUR 625.2 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
K6591505 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
K4952205 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
TTC39B sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
K2551105 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
ELISA kit for Human TTC39B (Tetratricopeptide Repeat Domain Protein 39B) |
ELK7779 |
ELK Biotech |
1 plate of 96 wells |
EUR 518.4 |
|
Description: A sandwich ELISA kit for detection of Tetratricopeptide Repeat Domain Protein 39B from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
K6591506 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
K6591507 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
K6591508 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
K4952206 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
K4952207 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Ttc39b sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
K4952208 |
ABM |
1.0 ug DNA |
EUR 200.4 |
TTC39B sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
K2551106 |
ABM |
1.0 ug DNA |
EUR 200.4 |
TTC39B sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
K2551107 |
ABM |
1.0 ug DNA |
EUR 200.4 |
TTC39B sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
K2551108 |
ABM |
1.0 ug DNA |
EUR 200.4 |
TTC39B Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV681782 |
ABM |
1.0 ug DNA |
EUR 818.4 |
TTC39B Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV681783 |
ABM |
1.0 ug DNA |
EUR 888 |
TTC39B Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV681784 |
ABM |
1.0 ug DNA |
EUR 888 |
[KO Validated] TTC11 Rabbit mAb |
A19666-100ul |
Abclonal |
100 ul |
EUR 492 |
[KO Validated] TTC11 Rabbit mAb |
A19666-200ul |
Abclonal |
200 ul |
EUR 685.2 |
[KO Validated] TTC11 Rabbit mAb |
A19666-20ul |
Abclonal |
20 ul |
EUR 265.2 |
[KO Validated] TTC11 Rabbit mAb |
A19666-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Rabbit pAbPC1 Rabbit pAb |
A14872-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC1 Rabbit pAb |
A14872-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC1 Rabbit pAb |
A14872-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC1 Rabbit pAb |
A14872-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC3 Rabbit pAb |
A18370-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC3 Rabbit pAb |
A18370-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC5 Rabbit pAb |
A9997-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC5 Rabbit pAb |
A9997-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPC4 Rabbit pAb |
A5948-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPC4 Rabbit pAb |
A5948-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rabbit pAbPN1 Rabbit pAb |
A6041-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rabbit pAbPN1 Rabbit pAb |
A6041-50ul |
Abclonal |
50 ul |
EUR 267.6 |
HNRRabbit pAb Rabbit pAb |
A17497-100ul |
Abclonal |
100 ul |
EUR 369.6 |
HNRRabbit pAb Rabbit pAb |
A17497-200ul |
Abclonal |
200 ul |
EUR 550.8 |
HNRRabbit pAb Rabbit pAb |
A17497-20ul |
Abclonal |
20 ul |
EUR 219.6 |
HNRRabbit pAb Rabbit pAb |
A17497-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rabbit Tetricopeptide repeat protein 27(TTC27) ELISA kit |
E04T0743-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Tetricopeptide repeat protein 27(TTC27) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rabbit Tetricopeptide repeat protein 27(TTC27) ELISA kit |
E04T0743-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Tetricopeptide repeat protein 27(TTC27) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rabbit Tetricopeptide repeat protein 27(TTC27) ELISA kit |
E04T0743-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Tetricopeptide repeat protein 27(TTC27) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
RAB8B Rabbit pAb |
A3678-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RAB8B Rabbit pAb |
A3678-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RAB8B Rabbit pAb |
A3678-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RAB8B Rabbit pAb |
A3678-50ul |
Abclonal |
50 ul |
EUR 267.6 |
RAB7B Rabbit pAb |
A17855-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RAB7B Rabbit pAb |
A17855-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RAB7B Rabbit pAb |
A17855-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RAB7B Rabbit pAb |
A17855-50ul |
Abclonal |
50 ul |
EUR 267.6 |
RAB5B Rabbit pAb |
A7447-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RAB5B Rabbit pAb |
A7447-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RAB5B Rabbit pAb |
A7447-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RAB5B Rabbit pAb |
A7447-50ul |
Abclonal |
50 ul |
EUR 267.6 |
RAB1B Rabbit pAb |
A7514-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RAB1B Rabbit pAb |
A7514-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RAB1B Rabbit pAb |
A7514-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RAB1B Rabbit pAb |
A7514-50ul |
Abclonal |
50 ul |
EUR 267.6 |
RB Rabbit pAb |
A10094-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RB Rabbit pAb |
A10094-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RB Rabbit pAb |
A10094-20ul |
Abclonal |
20 ul |
Ask for price |
RB Rabbit pAb |
A10094-50ul |
Abclonal |
50 ul |
Ask for price |
C6 Rabbit pAb |
A10170-100ul |
Abclonal |
100 ul |
EUR 369.6 |
C6 Rabbit pAb |
A10170-200ul |
Abclonal |
200 ul |
EUR 550.8 |
C6 Rabbit pAb |
A10170-20ul |
Abclonal |
20 ul |
EUR 219.6 |
C6 Rabbit pAb |
A10170-50ul |
Abclonal |
50 ul |
EUR 267.6 |
C2 Rabbit pAb |
A10186-100ul |
Abclonal |
100 ul |
EUR 369.6 |
C2 Rabbit pAb |
A10186-200ul |
Abclonal |
200 ul |
EUR 550.8 |
C2 Rabbit pAb |
A10186-20ul |
Abclonal |
20 ul |
EUR 219.6 |
C2 Rabbit pAb |
A10186-50ul |
Abclonal |
50 ul |
EUR 267.6 |
Rb Rabbit pAb |
A11409-100ul |
Abclonal |
100 ul |
EUR 369.6 |
Rb Rabbit pAb |
A11409-200ul |
Abclonal |
200 ul |
EUR 550.8 |
Rb Rabbit pAb |
A11409-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Rb Rabbit pAb |
A11409-50ul |
Abclonal |
50 ul |
EUR 267.6 |
HP Rabbit pAb |
A1571-100ul |
Abclonal |
100 ul |
EUR 369.6 |
HP Rabbit pAb |
A1571-200ul |
Abclonal |
200 ul |
EUR 550.8 |
HP Rabbit pAb |
A1571-20ul |
Abclonal |
20 ul |
EUR 219.6 |
HP Rabbit pAb |
A1571-50ul |
Abclonal |
50 ul |
EUR 267.6 |
F7 Rabbit pAb |
A16044-100ul |
Abclonal |
100 ul |
EUR 369.6 |
F7 Rabbit pAb |
A16044-200ul |
Abclonal |
200 ul |
EUR 550.8 |
F7 Rabbit pAb |
A16044-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Macular structural characteristics on the limits and outside the lesions include intrarinal hyperreflective points, macular sistoid edema, subretinal fluid and loss of ellipsoid zone (EZ). Selective EZ losses found in 6 of 12 eyes showed recovery in 4 eyes after receiving anti-virus treatment. In the eye of CMVR, there are microvascular abnormalities and microstructure in the macular area without cmvr lesions that are clinically seen. Our results provide interesting insights into Retina CMV infection.